Evidence map›Paper›PMID 39252921›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Risk of selection and timelines for the continued spread of artemisinin and partner drug resistance in Africa.

Oliver J Watson, Salome Muchiri, Abby Ward, Cecile Meier-Sherling, Victor Asua, Thomas Katairo, Tom Brewer, Gina Cuomo-Dannenburg, Peter Winskill, Jeffrey A Bailey and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Oliver J WatsonMRC Centre for Global Infectious Disease Analysis, Faculty of Medicine, Imperial College London, London, UK.
Salome MuchiriClinton Health Access Initiative, Boston, MA, 21127, USA.
Abby WardClinton Health Access Initiative, Boston, MA, 21127, USA.
Cecile Meier-SherlingCenter for Computational Molecular Biology, Brown University, Providence, RI, USA.
Victor AsuaInfectious Diseases Research Collaboration, Kampala, Uganda.
Thomas KatairoInfectious Diseases Research Collaboration, Kampala, Uganda.
Tom BrewerMRC Centre for Global Infectious Disease Analysis, Faculty of Medicine, Imperial College London, London, UK.
Gina Cuomo-DannenburgMRC Centre for Global Infectious Disease Analysis, Faculty of Medicine, Imperial College London, London, UK.
Peter WinskillMRC Centre for Global Infectious Disease Analysis, Faculty of Medicine, Imperial College London, London, UK.
Jeffrey A BaileyCenter for Computational Molecular Biology, Brown University, Providence, RI, USA.
Lucy OkellMRC Centre for Global Infectious Disease Analysis, Faculty of Medicine, Imperial College London, London, UK.
Graziella ScuduClinton Health Access Initiative, Boston, MA, 21127, USA.
Aaron M WoolseyClinton Health Access Initiative, Boston, MA, 21127, USA.

Funding

Artemisinin Resistance in Africa: its emergence and evolution in RwandaR01AI156267 · NIAID · BROWN UNIVERSITY · PI BAILEY, JEFFREY A., JULIANO, JONATHAN J · 2021 to 2024
$3.0M
NIAID NIH HHS R01 AI156267
6 · The paper itself

Abstract

The introduction of artemisinin combination therapies (ACTs) has significantly reduced the burden of

Identifiers

PMID39252921
PMCPMC11383480

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.